{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T03:57:03Z","timestamp":1784779023330,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00417-025-07059-2","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T10:59:45Z","timestamp":1768906785000},"page":"915-925","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of anti-VEGF therapy for Irvine-Gass syndrome: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"264","author":[{"given":"Daniel","family":"Balsby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Arnold-Vangsted","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil Alexander","family":"Rosen\u00f8rn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie Skovgaard","family":"Eriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan Javed","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese Gr\u00f8nh\u00f8j","family":"Krarup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2313-5648","authenticated-orcid":false,"given":"Oliver Niels","family":"Klefter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javad Nouri","family":"Hajari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6620-5365","authenticated-orcid":false,"given":"Yousif","family":"Subhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1488-4743","authenticated-orcid":false,"given":"Miklos","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"7059_CR1","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/0002-9394(53)90302-x","volume":"36","author":"SR Irvine","year":"1953","unstructured":"Irvine SR (1953) A newly defined vitreous syndrome following cataract surgery. Am J Ophthalmol 36:599\u2013619. https:\/\/doi.org\/10.1016\/0002-9394(53)90302-x","journal-title":"Am J Ophthalmol"},{"key":"7059_CR2","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1001\/archopht.1966.03850010648005","volume":"76","author":"JD Gass","year":"1966","unstructured":"Gass JD, Norton EW (1966) Cystoid macular edema and papilledema following cataract extraction. A fluorescein fundoscopic and angiographic study. Arch Ophthalmol 76:646\u2013661. https:\/\/doi.org\/10.1001\/archopht.1966.03850010648005","journal-title":"Arch Ophthalmol"},{"key":"7059_CR3","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ophtha.2015.10.001","volume":"123","author":"CJ Chu","year":"2016","unstructured":"Chu CJ, Johnston RL, Buscombe C, Sallam AB, Mohamed Q, Yang YC (2016) Risk factors and incidence of macular edema after cataract surgery: A database study of 81984 eyes. Ophthalmology 123:316\u2013323. https:\/\/doi.org\/10.1016\/j.ophtha.2015.10.001","journal-title":"Ophthalmology"},{"key":"7059_CR4","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1016\/j.ophtha.2015.05.014","volume":"122","author":"SJ Kim","year":"2015","unstructured":"Kim SJ, Schoenberger SD, Thorne JE, Ehlers JP, Yeh S, Bakri SJ (2015) Topical nonsteroidal Anti-inflammatory drugs and cataract surgery: A report by the American academy of ophthalmology. Ophthalmology 122:2159\u20132168. https:\/\/doi.org\/10.1016\/j.ophtha.2015.05.014","journal-title":"Ophthalmology"},{"key":"7059_CR5","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.2147\/cia.S111761","volume":"11","author":"A Grzybowski","year":"2016","unstructured":"Grzybowski A, Sikorski BL, Ascaso FJ, Huerva V (2016) Pseudophakic cystoid macular edema: update 2016. Clin Interv Aging 11:1221\u20131229. https:\/\/doi.org\/10.2147\/cia.S111761","journal-title":"Clin Interv Aging"},{"key":"7059_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/ICU.0b013e32834cd5f8","volume":"23","author":"Y Yonekawa","year":"2012","unstructured":"Yonekawa Y, Kim IK (2012) Pseudophakic cystoid macular edema. Curr Opin Ophthalmol 23:26\u201332. https:\/\/doi.org\/10.1097\/ICU.0b013e32834cd5f8","journal-title":"Curr Opin Ophthalmol"},{"key":"7059_CR7","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/ceo.13513","volume":"47","author":"JV Han","year":"2019","unstructured":"Han JV, Patel DV, Squirrell D, McGhee CN (2019) Cystoid macular oedema following cataract surgery: A review. Clin Exp Ophthalmol 47:346\u2013356. https:\/\/doi.org\/10.1111\/ceo.13513","journal-title":"Clin Exp Ophthalmol"},{"key":"7059_CR8","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/s41433-020-0908-y","volume":"35","author":"OO Erikitola","year":"2021","unstructured":"Erikitola OO, Siempis T, Foot B, Lockington D (2021) The incidence and management of persistent cystoid macular oedema following uncomplicated cataract surgery-a Scottish ophthalmological surveillance unit study. Eye (Lond) 35:584\u2013591. https:\/\/doi.org\/10.1038\/s41433-020-0908-y","journal-title":"Eye (Lond)"},{"key":"7059_CR9","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/j.jcrs.2012.07.029","volume":"38","author":"M Packer","year":"2012","unstructured":"Packer M, Lowe J, Fine H (2012) Incidence of acute postoperative cystoid macular edema in clinical practice. J Cataract Refract Surg 38:2108\u20132111. https:\/\/doi.org\/10.1016\/j.jcrs.2012.07.029","journal-title":"J Cataract Refract Surg"},{"key":"7059_CR10","first-page":"557","volume":"96","author":"AJ Flach","year":"1998","unstructured":"Flach AJ (1998) The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc 96:557\u2013634","journal-title":"Trans Am Ophthalmol Soc"},{"key":"7059_CR11","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.jcrs.2007.05.013","volume":"33","author":"BA Henderson","year":"2007","unstructured":"Henderson BA, Kim JY, Ament CS, Ferrufino-Ponce ZK, Grabowska A, Cremers SL (2007) Clinical pseudophakic cystoid macular edema. Risk factors for development and duration after treatment. J Cataract Refract Surg 33:1550\u20131558. https:\/\/doi.org\/10.1016\/j.jcrs.2007.05.013","journal-title":"J Cataract Refract Surg"},{"key":"7059_CR12","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1016\/s0886-3350(99)00196-0","volume":"25","author":"PG Ursell","year":"1999","unstructured":"Ursell PG, Spalton DJ, Whitcup SM, Nussenblatt RB (1999) Cystoid macular edema after phacoemulsification: relationship to blood-aqueous barrier damage and visual acuity. J Cataract Refract Surg 25:1492\u20131497. https:\/\/doi.org\/10.1016\/s0886-3350(99)00196-0","journal-title":"J Cataract Refract Surg"},{"key":"7059_CR13","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/sj.eye.6701864","volume":"20","author":"HY Ching","year":"2006","unstructured":"Ching HY, Wong AC, Wong CC, Woo DC, Chan CW (2006) Cystoid macular oedema and changes in retinal thickness after phacoemulsification with optical coherence tomography. Eye (Lond) 20:297\u2013303. https:\/\/doi.org\/10.1038\/sj.eye.6701864","journal-title":"Eye (Lond)"},{"key":"7059_CR14","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/s0886-3350(03)00582-0","volume":"30","author":"CL Lobo","year":"2004","unstructured":"Lobo CL, Faria PM, Soares MA, Bernardes RC, Cunha-Vaz JG (2004) Macular alterations after small-incision cataract surgery. J Cataract Refract Surg 30:752\u2013760. https:\/\/doi.org\/10.1016\/s0886-3350(03)00582-0","journal-title":"J Cataract Refract Surg"},{"key":"7059_CR15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/00006982-198808030-00001","volume":"8","author":"JD Bradford","year":"1988","unstructured":"Bradford JD, Wilkinson CP, Bradford RH Jr (1988) Cystoid macular edema following extracapsular cataract extraction and posterior chamber intraocular lens implantation. Retina 8:161\u2013164. https:\/\/doi.org\/10.1097\/00006982-198808030-00001","journal-title":"Retina"},{"key":"7059_CR16","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1186\/s12886-023-03113-x","volume":"23","author":"G Ahmadyar","year":"2023","unstructured":"Ahmadyar G, Carlson JJ, Kimura A, Alobaidi A, Hallak J, Hansen RN (2023) Real-world treatment patterns and economic burden of post-cataract macular edema. BMC Ophthalmol 23:380. https:\/\/doi.org\/10.1186\/s12886-023-03113-x","journal-title":"BMC Ophthalmol"},{"key":"7059_CR17","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/iae.0b013e3181b8628e","volume":"30","author":"KA Warren","year":"2010","unstructured":"Warren KA, Bahrani H, Fox JE (2010) NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. Retina 30:260\u2013266. https:\/\/doi.org\/10.1097\/iae.0b013e3181b8628e","journal-title":"Retina"},{"key":"7059_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/IAE.0b013e3181fd9740","volume":"31","author":"HN Shelsta","year":"2011","unstructured":"Shelsta HN, Jampol LM (2011) Pharmacologic therapy of pseudophakic cystoid macular edema: 2010 update. Retina 31:4\u201312. https:\/\/doi.org\/10.1097\/IAE.0b013e3181fd9740","journal-title":"Retina"},{"key":"7059_CR19","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.ophtha.2014.04.035","volume":"121","author":"L Kessel","year":"2014","unstructured":"Kessel L, Tendal B, J\u00f8rgensen KJ, Erngaard D, Flesner P, Andresen JL, Hjortdal J (2014) Post-cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti-inflammatory eye drops: a systematic review. Ophthalmology 121:1915\u20131924. https:\/\/doi.org\/10.1016\/j.ophtha.2014.04.035","journal-title":"Ophthalmology"},{"key":"7059_CR20","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.ophtha.2009.04.006","volume":"116","author":"JF Arevalo","year":"2009","unstructured":"Arevalo JF, Maia M, Garcia-Amaris RA, Roca JA, Sanchez JG, Berrocal MH, Wu L (2009) Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American collaborative retina study group results. Ophthalmology 116:1481\u20131487 1487.e1481. https:\/\/doi.org\/10.1016\/j.ophtha.2009.04.006","journal-title":"Ophthalmology"},{"key":"7059_CR21","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jcrs.2007.08.021","volume":"34","author":"MS Spitzer","year":"2008","unstructured":"Spitzer MS, Ziemssen F, Yoeruek E, Petermeier K, Aisenbrey S, Szurman P (2008) Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema. J Cataract Refract Surg 34:70\u201375. https:\/\/doi.org\/10.1016\/j.jcrs.2007.08.021","journal-title":"J Cataract Refract Surg"},{"key":"7059_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/IAE.0b013e31818a1fbc","volume":"29","author":"A Barone","year":"2009","unstructured":"Barone A, Russo V, Prascina F, Delle Noci N (2009) Short-term safety and efficacy of intravitreal bevacizumab for pseudophakic cystoid macular edema. Retina 29:33\u201337. https:\/\/doi.org\/10.1097\/IAE.0b013e31818a1fbc","journal-title":"Retina"},{"key":"7059_CR23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3109\/09273948.2014.898775","volume":"23","author":"PG Mitropoulos","year":"2015","unstructured":"Mitropoulos PG, Chatziralli IP, Peponis VG, Drakos E, Parikakis EA (2015) Intravitreal Ranibizumab for the treatment of Irvine-Gass syndrome. Ocul Immunol Inflamm 23:225\u2013231. https:\/\/doi.org\/10.3109\/09273948.2014.898775","journal-title":"Ocul Immunol Inflamm"},{"key":"7059_CR24","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1016\/j.jcrs.2007.07.046","volume":"33","author":"JF Arevalo","year":"2007","unstructured":"Arevalo JF, Garcia-Amaris RA, Roca JA, Sanchez JG, Wu L, Berrocal MH, Maia M (2007) Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema: pilot study of the Pan-American collaborative retina study group. J Cataract Refract Surg 33:2098\u20132105. https:\/\/doi.org\/10.1016\/j.jcrs.2007.07.046","journal-title":"J Cataract Refract Surg"},{"key":"7059_CR25","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"7059_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JPT Higgins","year":"2019","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (2019) Cochrane handbook for systematic reviews of interventions. Wiley, Chichester (UK)"},{"key":"7059_CR27","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1038\/s41433-020-0783-6","volume":"34","author":"S Tiew","year":"2020","unstructured":"Tiew S, Lim C, Sivagnanasithiyar T (2020) Using an excel spreadsheet to convert Snellen visual acuity to LogMAR visual acuity. Eye (Lond) 34:2148\u20132149. https:\/\/doi.org\/10.1038\/s41433-020-0783-6","journal-title":"Eye (Lond)"},{"key":"7059_CR28","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S0002-9394(02)01825-1","volume":"135","author":"RW Beck","year":"2003","unstructured":"Beck RW, Moke PS, Turpin AH, Ferris FL III, SanGiovanni JP, Johnson CA, Birch EE, Chandler DL, Cox TA, Blair RC, Kraker RT (2003) A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol. Am J Ophthalmol 135:194\u2013205. https:\/\/doi.org\/10.1016\/S0002-9394(02)01825-1","journal-title":"Am J Ophthalmol"},{"key":"7059_CR29","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.18240\/ijo.2020.10.12","volume":"13","author":"F Akay","year":"2020","unstructured":"Akay F, I\u015f\u0131k MU, Akmaz B, G\u00fcven YZ (2020) Comparison of intravitreal anti-vascular endothelial growth factor agents and treatment results in Irvine-Gass syndrome. Int J Ophthalmol 13:1586\u20131591. https:\/\/doi.org\/10.18240\/ijo.2020.10.12","journal-title":"Int J Ophthalmol"},{"key":"7059_CR30","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1177\/11206721231185909","volume":"34","author":"B Karasu","year":"2024","unstructured":"Karasu B, Kesim E, Celebi ARC (2024) The efficacy of different anti-vascular endothelial growth factor agents, and dexamethasone implant therapy in patients with serous retinal detachment caused by Irvine-Gass syndrome. Eur J Ophthalmol 34:510\u2013523. https:\/\/doi.org\/10.1177\/11206721231185909","journal-title":"Eur J Ophthalmol"},{"key":"7059_CR31","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ophtha.2017.12.002","volume":"125","author":"G Staurenghi","year":"2018","unstructured":"Staurenghi G, Lai TYY, Mitchell P, Wolf S, Wenzel A, Li J, Bhaumik A, Hykin PG (2018) Efficacy and safety of Ranibizumab 0.5\u00a0mg for the treatment of macular edema resulting from uncommon causes: Twelve-Month findings from PROMETHEUS. Ophthalmology 125:850\u2013862. https:\/\/doi.org\/10.1016\/j.ophtha.2017.12.002","journal-title":"Ophthalmology"},{"key":"7059_CR32","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) (2024) Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024 http:\/\/www.cochrane.org\/handbook"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-07059-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-025-07059-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-07059-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T08:37:11Z","timestamp":1773909431000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-025-07059-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7059"],"URL":"https:\/\/doi.org\/10.1007\/s00417-025-07059-2","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"4 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. According to Danish law, institutional review board approval is not required for systematic reviews.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and concent to participate"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CRD42025643460.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"PROSPERO registration ID"}},{"value":"Author M.S. declares to have served as an advisory board member for Novartis, Bayer and Roche, to have acted as a consultant for AbbVie, received speaker fees from AbbVie and Roche, and received travel grants from AbbVie, Bayer and Roche, not related to this work. Author Y.S. declares to have received speaker fees from Bayer and Roche, not related to this work. All other authors declare that no potential conflicts of interest exist in relation to this work.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}